Market News & Trends
LSNE-León Receives Approval From AEMPS to Manufacture Biotechnology-Based Therapeutic Products
LSNE Contract Manufacturing recently announced that the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved the manufacturing of clinical-stage biotechnology-based therapeutic products at…
Novavax & Canada Reach Agreement in Principle to Acquire COVID-19 Vaccine
Novavax, Inc. recently announced it has reached an agreement in principle with the Government of Canada to supply up to 76 million doses of NVX-CoV2373,…
First Patient Dosed in AstraZeneca’s Phase 3 COVID-19 Vaccine Trial
Headlands Research is pleased to announce that on Friday, Aug. 28, its JEM Research Institute clinical trial site in Lake Worth, FL, successfully dosed the…
Catalent Biologics Invests $50 Million to Add Third High-Speed Vial Line
Catalent recently announced it is investing $50 million to install an additional high-speed vial filling line at its Bloomington, IN, facility. The new line is…
Micron Biomedical Progresses With Clinical Evaluation of its Technology for Measles-Rubella Vaccination
Micron Biomedical, Inc. (Micron) recently received a second tranche of funding ($2.6 million) to continue clinical development of its microneedle-based technology for measles and rubella…
Rain Therapeutics Announces License Agreement for the Development of Proprietary RAD52 Inhibitors
Rain Therapeutics Inc. recently announced the signing of an exclusive, worldwide license agreement of a Drexel University research program to Rain for small molecule inhibitors of….
Cancer Genetics & StemoniX Sign Definitive Agreement to Merge
Cancer Genetics, Inc. and StemoniX, Inc. recently announced the entry into a definitive merger agreement. Cancer Genetics is a leader in drug discovery and….
Catalent Signs Agreement With AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine
Catalent, Inc. recently announced that Catalent Cell & Gene Therapy will provide drug substance manufacturing to AstraZeneca for the University of Oxford’s adenovirus vector-based COVID-19 vaccine….
Trishula Therapeutics Established to Advance Novel TTX-030, an Anti-CD39 Antibody
Recently, Trishula Therapeutics was launched to be solely dedicated to the development of TTX-030, a first-in-class anti-CD39 antibody, being studied in advanced cancers. The new…
Independent Studies Confirm Low Levels of Immune System Protein, Gelsolin, Associated With COVID-19 Severity
BioAegis Therapeutics Inc. recently announced that recent publications of independent studies have reported that low levels of gelsolin are associated with severe illness and organ…
Onconova Therapeutics Announces Topline Results From Pivotal Phase 3 INSPIRE Trial
Onconova Therapeutics, Inc. recently announced that INSPIRE, the company’s pivotal Phase 3 study assessing the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS)…
EDAP Announces Approval for Phase 2 Study
EDAP TMS SA recently announced it has received approval from French health authorities to initiate a Phase 2 multicenter clinical trial evaluating its Focal One…
BioAge Discovers Key Pathway & Identifies Promising Phase 2-Ready Drug to Treat & Reverse Immune Aging, a Root Cause of COVID-19 Morbidity & Mortality in Older Patients
BioAge Labs, Inc. recently announced it has in-licensed a clinical-stage therapy with significant promise and potential in treating immune aging in older patients hospitalized with…
AbbVie Submits Regulatory Application to FDA for RINVOQ
AbbVie recently announced it has submitted an application for a new indication to the US FDA for RINVOQ (upadacitinib; 15 mg, once daily), a selective…
ANA Therapeutics & Quotient Sciences Announce Manufacturing Partnership
ANA Therapeutics, a Silicon Valley-based biotech start-up, and Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, recently announced a partnership to support the….
EyePoint Pharmaceuticals Receives $9.5 Million From Ocumension Therapeutics Under Expanded License Agreements
EyePoint Pharmaceuticals, Inc. and Ocumension Therapeutics recently announced the expansion of their exclusive license agreements for the development and commercialization of….
Humanetics Corporation & Pharmaceutics International, Inc. Announce Partnership
Humanetics Corporation and Pharmaceutics International, Inc. (Pii) will work together to support a clinical trial of BIO 300 in COVID-19 patients…..
Ingenza Meets a key Milestone in the Deployment of Novel Cost-Effective COVID-19 Vaccine Technology
Edinburgh-based biotech company Ingenza Ltd. has made a significant breakthrough in the race to develop and manufacture a cost-effective vaccine against SARS-CoV-2, the virus responsible for the current COVID-19 pandemic…..
Organicell Provides Phase 1/2 Clinical Trial Update
Organicell Regenerative Medicine, Inc. recently announced it has partnered with Alternative Research Associates, LLC and Larkin Hospital in Miami, FL, to initiate a randomized, double-blinded,…
TFF Pharmaceuticals Enters into Worldwide Licensing Agreement With UNION Therapeutics
TFF Pharmaceuticals, Inc. recently announced it has entered into a worldwide exclusive licensing agreement with UNION therapeutics A/S (UNION) for its TFF technology used in…
